Skip to content
DataLookout
Menu

NCT07940166

A Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and Pharmacokinetics

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Incidence of adverse events (AEs)
Timeframe: Approximately 2 years.
Maximum tolerated dose (MTD)
Timeframe: Approximately 1 year.
Recommended Phase II Dose (RP2D)
Timeframe: Approximately 2 years.

Secondary (18)

Peak concentration (Cmax)
Time to peak concentration (Tmax)
Trough concentration (Ctrough)
Peak-to-trough fluctuation (PTF)
Average plasma concentration (Cavg)
Show 13 moreShow less
Area under the concentration-time curve from time 0 to t (AUC0-t, where t is the time of the last measurable concentration)
Area under the concentration-time curve from time 0 to infinity (AUC0-inf)
Area under the concentration-time curve during one dosing interval (tau) at steady state (AUCtau)
Apparent clearance (CL/F, CLss/F)
Apparent volume of distribution (Vz/F, Vss/F)
Terminal elimination half-life (t1/2)
Terminal elimination rate constant (λz)
Accumulation ratio (Rac)
Objective Response Rate (ORR)
Duration of Response (DoR)
Disease Control Rate (DCR)
Progression-Free Survival (PFS)
Overall Survival (OS)

Arms and interventions

HRS-8046 GroupExperimental

HRS-8046.

Drugs: HRS-8046 Tablet

Sites

2 sites in 1 country